##  [Facilitating Overseas On-Site NMPA Inspection for a Blood-Derived Product to Secure Market Authorization in China](/index%2ephp/success-stories/facilitating-overseas-on-site-nmpa-inspection-for-a-blood-derived-product-to-secure-market-authorization-in-china) 

# Facilitating Overseas On-Site NMPA Inspection for a Blood-Derived Product to Secure Market Authorization in China

Delivering comprehensive China Regulatory Affairs support, NMPA inspection readiness, overseas GMP audit coordination, Regulatory compliance consulting, and market authorization support for a high-risk blood-derived product while ensuring successful completion of an overseas on-site inspection and uninterrupted market access in China.





![]()









### Zero



compliance flags reported during the inspection process







### End-to-end



Regulatory dossier preparation and audit coordination support







### Real-time



bilingual Regulatory communication during inspection activities













![Client Overview]()



![Icon]()  

## Client Overview



A U.S.-China-based biopharmaceutical company required specialized China Regulatory Affairs and NMPA inspection support for a blood-derived therapy classified as a high-risk biological product. The company needed assistance with Regulatory dossier preparation, overseas on-site inspection readiness, audit coordination, Health Authority communication, and compliance risk mitigation to support continued market authorization and Regulatory compliance in China.











![Background Icon]()  

## Background



As part of China's Regulatory oversight for high-risk biological products, the National Medical Products Administration (NMPA) selected the client's blood-derived product for an overseas on-site inspection. Such inspections are a critical component of China's Regulatory review process for certain biologics and blood products and can directly impact market authorization status.

The client required an experienced Regulatory partner capable of coordinating global inspection activities, preparing inspection-ready documentation, supporting interactions with NMPA officials, and ensuring compliance with evolving Chinese Regulatory expectations for blood-derived and biologic products.





![Scope Icon]()  

## Services in Scope



![]()

NMPA Inspection Readiness and Regulatory Support



![]()

Regulatory Dossier Preparation and Documentation Review



![]()

Overseas On-Site Inspection Coordination



![]()

Audit Planning and Regulatory Operations Management



![]()

Bilingual Regulatory Communication Support



![]()

Health Authority Query and Issue Resolution Support



![]()

Compliance Risk Assessment and Mitigation



![]()

Market Authorization and Regulatory Compliance Support















![Challenge]()



![Challenge]()

## Challenge



![Challenge]()

**High-Risk Product Classification** The blood-derived therapy was classified as a high-risk biological product by the NMPA, triggering an overseas Regulatory inspection and increasing scrutiny throughout the review process.





![Challenge]()

**Stringent NMPA Regulatory Expectations** Any misalignment with inspection requirements, documentation standards, or GMP expectations could have resulted in Regulatory delays, inspection findings, or loss of market qualification in China.





![Challenge]()

**Complex Global Inspection Coordination** Managing communication, logistics, documentation, and stakeholder alignment across multiple international locations and NMPA officials required extensive Regulatory project management and operational oversight.





![Challenge]()

**Real-Time Regulatory Communication Requirements** The inspection process required immediate bilingual communication and issue resolution support to address Regulatory questions and ensure alignment during audit activities.















![Challenge]()

## Solution



1

![Challenge]()

##### Regulatory Dossier Preparation

Prepared and reviewed the complete Regulatory dossier to align with NMPA inspection expectations and support audit readiness.





2

![Challenge]()

##### Overseas Inspection Coordination

Managed scheduling, planning, and execution of the overseas on-site inspection while coordinating activities between global stakeholders and NMPA officials.





3

![Challenge]()

##### Real-Time Bilingual Regulatory Support

Provided bilingual communication support during the inspection process to facilitate seamless discussions, query resolution, and Regulatory alignment.





4

![Challenge]()

##### Compliance Risk Mitigation

Identified and addressed potential compliance risks proactively to reduce the likelihood of inspection findings, delays, or Regulatory disruptions.





5

![Challenge]()

##### Regulatory Operations Management

Delivered end-to-end Regulatory operations support to ensure smooth execution of inspection activities and uninterrupted progress toward market authorization.











![Challenge]()

## Impact



Freyr's support enabled the client to successfully navigate a critical NMPA overseas inspection while strengthening Regulatory compliance, operational readiness, and market access continuity in China.



![Challenge]()

##### Regulatory Excellence 

- Achieved successful completion of the NMPA overseas inspection
- Ensured alignment with China Regulatory requirements and inspection expectations
- Delivered inspection support with zero compliance flags
- Strengthened audit readiness and Regulatory governance





![Challenge]()

##### Faster Submission Execution 

- Facilitated timely completion of inspection activities
- Accelerated issue resolution through proactive Regulatory engagement
- Minimized risks associated with inspection delays and non-compliance





![Challenge]()

##### Operational Efficiency 

- Streamlined inspection planning, coordination, and communication workflows
- Improved collaboration between global stakeholders and Regulatory authorities
- Enhanced visibility into inspection readiness and compliance activities





![Challenge]()

##### Business Value 

- Maintained uninterrupted market authorization support in China
- Reduced Regulatory risk for a high-priority blood-derived therapy
- Strengthened the client's China market access and commercialization strategy
- Supported long-term Regulatory compliance and business continuity